Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN4005 in advanced solid tumors and lymphoma
NCT04999384Phase 1Recruiting
- Sponsor
- Adlai Nortye
- Start
- Sep 2021
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of an4005 in solid tumor (advanced stage) and lymphoma (6 arms), sponsored by Adlai Nortye. Primary endpoints: Adverse Events at 1 year, Dose Limiting Toxicities at 28 days and 1 more. Started Sep 2021; status: recruiting.
02
Drugs
an4005
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT04999384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04999384.